Literature DB >> 22090661

Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.

Johannes A N Dorresteijn1, Frank L J Visseren, Paul M Ridker, Nina P Paynter, Annemarie M J Wassink, Julie E Buring, Yolanda van der Graaf, Nancy R Cook.   

Abstract

AIMS To identify women who benefit from aspirin 100 mg on alternate days for primary prevention of vascular events by using treatment effect prediction based on individual patient characteristics. METHODS AND RESULTS Randomized controlled trial data from the Women's Health Study were used to predict treatment effects for individual women in terms of absolute risk reduction for major cardiovascular events (i.e. myocardial infarction, stroke, or cardiovascular death). Predictions were based on existing risk scores, i.e. Framingham (FRS), and Reynolds (RRS), and on a newly developed prediction model. The net benefit of different aspirin treatment-strategies was compared: (i) treat no one, (ii) treat everyone, (iii) treatment according to the current guidelines (i.e. selective treatment of women >65 years of age or having >10% FRS), and (iv) prediction-based treatment (i.e. selective treatment of patients whose predicted treatment effect exceeds a given decision threshold). The predicted reduction in 10-year absolute risk for major cardiovascular events was <1% in 97.8% of 27 939 study subjects when based on the refitted FRS, in 97.0% when based on the refitted RRS, and in 90.0% when based on the newly developed model. Of the treatment strategies considered, only prediction-based treatment using the newly developed model and selective treatment of women >65 years of age yielded more net benefit than treating no one, provided that the 10-year number-willing-to-treat (NWT) to prevent one cardiovascular event was above 50. CONCLUSION Aspirin was ineffective or even harmful in the majority of patients. Age was positively related to treatment effect, whereas current smoking and baseline risk for cardiovascular events were not. When the NWT is 50 or lower, the aspirin treatment strategy that is associated with optimal net benefit in primary prevention of vascular events in women is to treat none.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22090661      PMCID: PMC3227855          DOI: 10.1093/eurheartj/ehr423

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  17 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

3.  European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-09

4.  Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Authors:  Jeffrey S Berger; Maria C Roncaglioni; Fausto Avanzini; Ierta Pangrazzi; Gianni Tognoni; David L Brown
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

5.  Aspirin: a historical and contemporary therapeutic overview.

Authors:  Valentin Fuster; Joseph M Sweeny
Journal:  Circulation       Date:  2011-02-22       Impact factor: 29.690

6.  Decision curve analysis: a novel method for evaluating prediction models.

Authors:  Andrew J Vickers; Elena B Elkin
Journal:  Med Decis Making       Date:  2006 Nov-Dec       Impact factor: 2.583

7.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

8.  Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

9.  Estimating treatment effects for individual patients based on the results of randomised clinical trials.

Authors:  Johannes A N Dorresteijn; Frank L J Visseren; Paul M Ridker; Annemarie M J Wassink; Nina P Paynter; Ewout W Steyerberg; Yolanda van der Graaf; Nancy R Cook
Journal:  BMJ       Date:  2011-10-03

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

View more
  10 in total

Review 1.  Management of carotid stenosis in women: consensus document.

Authors:  Paola De Rango; Martin M Brown; Didier Leys; Leys Didier; Virginia J Howard; Wesley S Moore; Maurizio Paciaroni; Peter Ringleb; Caron Rockman; Valeria Caso
Journal:  Neurology       Date:  2013-06-11       Impact factor: 9.910

Review 2.  Primary and secondary prevention of ischemic heart disease in women.

Authors:  Priya Kohli
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

3.  Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.

Authors:  Nancy R Cook; I-Min Lee; Shumin M Zhang; M Vinayaga Moorthy; Julie E Buring
Journal:  Ann Intern Med       Date:  2013-07-16       Impact factor: 25.391

Review 4.  Leveraging information from genetic risk scores of coronary atherosclerosis.

Authors:  Themistocles L Assimes; Elias L Salfati; Liana C Del Gobbo
Journal:  Curr Opin Lipidol       Date:  2017-04       Impact factor: 4.776

5.  Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.

Authors:  Rob C M van Kruijsdijk; Frank L J Visseren; Paul M Ridker; Johannes A N Dorresteijn; Julie E Buring; Yolanda van der Graaf; Nancy R Cook
Journal:  Heart       Date:  2014-12-04       Impact factor: 5.994

6.  Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials.

Authors:  James F Burke; Rodney A Hayward; Jason P Nelson; David M Kent
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-01-14

Review 7.  Role of aspirin in primary prevention of cardiovascular disease.

Authors:  Carlo Patrono; Colin Baigent
Journal:  Nat Rev Cardiol       Date:  2019-06-26       Impact factor: 32.419

8.  Utility of different cardiovascular disease prediction models in rheumatoid arthritis.

Authors:  A Purcarea; S Sovaila; G Udrea; E Rezus; A Gheorghe; C Tiu; V Stoica
Journal:  J Med Life       Date:  2014 Oct-Dec

Review 9.  A systematic review of aspirin in primary prevention: is it time for a new approach?

Authors:  Carlos Brotons; Robert Benamouzig; Krzysztof J Filipiak; Volker Limmroth; Claudio Borghi
Journal:  Am J Cardiovasc Drugs       Date:  2015-04       Impact factor: 3.571

10.  Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines.

Authors:  Tsung Yu; Daniela Vollenweider; Ravi Varadhan; Tianjing Li; Cynthia Boyd; Milo A Puhan
Journal:  BMC Med       Date:  2013-01-09       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.